COMMUNIQUÉS West-GlobeNewswire
-
BriaCell Presentations Highlight Positive Clinical Data for Bria-IMT™ at ASCO 2026
22/05/2026 -
Arch Biopartners announces Royal Columbian Hospital has dosed its first patient in its Phase II cardiac surgery-associated AKI trial
22/05/2026 -
Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference
22/05/2026 -
BioStem Technologies Announces $2.5 Million Private Placement Financing with its First Institutional Investor
22/05/2026 -
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
22/05/2026 -
American Shared Hospital Services Announces Annual Shareholder Meeting to be Held on June 24, 2026
22/05/2026 -
CHMP issues positive opinion for JASCAYD® (nerandomilast), bringing a new IPF and PPF therapy closer to patients in the EU
22/05/2026 -
Repligen Corporation to Present at William Blair 46th Annual Growth Stock Conference
22/05/2026 -
2026 ASCO | Pivotal Data of InnoCare's Novel BCL2 Inhibitor Mesutoclax Released
22/05/2026 -
FibroBiologics Presents Preclinical Data Demonstrating Durable Immunomodulation in Psoriasis at the Society for Investigative Dermatology 2026 Annual Meeting
22/05/2026 -
Assembly Biosciences Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants
22/05/2026 -
Ebola Outbreak “Spreading at Alarming Speed,” WHO Warns — Growing Global Health Emergencies Highlight Rising Need for TOMI’s SteraMist Technology
22/05/2026 -
STORM Therapeutics to Present Promising Phase 1 Sarcoma Data Demonstrating Activity of First‑in‑Class METTL3 Inhibitor STC‑15 at ASCO 2026
22/05/2026 -
China approves HERNEXEOS® as first targeted oral treatment option for HER2-mutant advanced NSCLC at initial diagnosis
22/05/2026 -
BioNTech to Showcase Progress Across Late-Stage Oncology Pipeline at the 2026 ASCO Annual Meeting
22/05/2026 -
CROSSJCROSSJECT annonce le succès d’une augmentation de capital et d’une émission de bons de souscription d’actions (BSA) au profit d’investisseurs pour un montant de 15 millions d’euros
22/05/2026 -
OSE Immunotherapeutics Reports Positive Topline Results of TEDOVA Phase 2 Trial with Tedopi® in Recurrent Ovarian Cancer
22/05/2026 -
ANGEL Introduces X2 Water Filter System with Advanced Tankless 7-Stage Filtration and 99% PFAS Reduction
22/05/2026 -
OSE Immunotherapeutics annonce les résultats de Topline positifs de l'étude de Phase 2 TEDOVA de Tedopi® dans le cancer de l’ovaire en rechute
22/05/2026
Pages